HHGC
RVNC

Hunting Hill Global Capital’s Revance Therapeutics, Inc. RVNC Stock Holding History

Hunting Hill Global Capital’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-57,222
Closed -$147K – 107
2024
Q2 		$147K Buy
57,222
+14,702
+35% +$50.2K 0.07% 87
2024
Q1 		$209K Sell
42,520
-7,125
-14% -$42.2K 0.1% 94
2023
Q4 		$436K Sell
49,645
-14,116
-22% -$116K 0.18% 72
2023
Q3 		$731K Buy
+63,761
New +$1.23M 0.24% 49

Other funds holding RVNC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

Hunting Hill Global Capital's RVNC Position: Q3 2024 in Review

Hunting Hill Global Capital sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2024, closing a stake of 57,222 shares — an estimated $147K sold.

Hunting Hill Global Capital first reported a position in RVNC in Q3 2023 and held it in 4 quarters. The position peaked at $731K in Q3 2023. 201 funds tracked by Wall St. Rank hold RVNC as of Q3 2024.

  • Hunting Hill Global Capital reported no remaining Revance Therapeutics, Inc. position as of Q3 2024 after selling out during the quarter.
  • Hunting Hill Global Capital sold 57,222 Revance Therapeutics, Inc. shares in Q3 2024, an estimated $147K.
  • Hunting Hill Global Capital first reported a position in Revance Therapeutics, Inc. in Q3 2023 and held it in 4 quarters.
  • Hunting Hill Global Capital's Revance Therapeutics, Inc. position peaked at $731K in Q3 2023.
  • 201 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2024.

Based on Hunting Hill Global Capital's 13F filing for Q3 2024, filed 14 Nov 2024.